Olaparib
- Generic Name
- Olaparib
- Brand Names
- Lynparza
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23FN4O3
- CAS Number
- 763113-22-0
- Unique Ingredient Identifier
- WOH1JD9AR8
- Background
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...
- Indication
Ovarian cancer
Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
- Associated Therapies
- Maintenance therapy
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2
- Registration Number
- NCT04951492
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
D9319C00001- 1L OC Mono Global RCT
- Conditions
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 366
- Registration Number
- NCT04884360
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 152
- Registration Number
- NCT04858334
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 13
- Registration Number
- NCT04826198
- Locations
- 🇫🇷
CHU Jean Minjoz, Besançon, Besancon, France
🇫🇷Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France
🇫🇷Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 3
- Registration Number
- NCT04801966
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-08-23
- Target Recruit Count
- 38
- Registration Number
- NCT04753879
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT04748042
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
- Conditions
- Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Mucinous AdenocarcinomaRecurrent Fallopian Tube Transitional Cell Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyDrug: Cediranib MaleateProcedure: Computed Tomography with ContrastProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingBiological: DurvalumabProcedure: Multigated Acquisition ScanDrug: PaclitaxelDrug: Pegylated Liposomal Doxorubicin HydrochlorideDrug: Topotecan HydrochlorideDrug: Olaparib
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT04739800
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Memorial Medical Center, Modesto, California, United States
🇺🇸Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT04728230
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.